Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 2107-2113

  Rodriguez Jr , Carlos O ^a   Legha, Jaswinder K ^a   Estey, Elihu ^a   Keating, Michael J ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 METHOXY ARABINOFURANOSYLPURINE; FLUDARABINE; GUANINE ARABINOSIDE; GUANOSINE TRIPHOSPHATE; NELARABINE; PRODRUG; PURINE NUCLEOSIDE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRACELLULAR RECORDING; LEUKEMIA; LEUKEMIA CELL; LYMPHOCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; ARABINONUCLEOTIDES; BIOTRANSFORMATION; GUANOSINE TRIPHOSPHATE; HUMANS; KINETICS; LEUKEMIA; LEUKEMIA, B-CELL; LEUKEMIA, MYELOID;

EID: 1842373912     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Giblett, E. R., Anderson, J. E., Cohen, F., Pollara, B., and Meuwissen, H. J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet, 2: 1067-1069, 1972.
2. Giblett, E. R., Ammann, A. J., Wara, D. W., Sandman, R., and Diamond, L. K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet, 1: 1010-1013, 1975.
3. Ullman, B., Gudas, L. J., Clift, S. M., and Martin, D. W., Jr. Isolation and characterization of purine nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc. Natl. Acad. Sci. USA, 76: 1074-1078, 1979.
4. Reist, E. J., and Goodman, L. Synthesis of 9-β-D-arabinofuranosylguanine. Biochemistry, 3: 15-18, 1964.
5. Lambe, C. U., Averett, D. R., Paff, M. T., Reardon, J. E., Wilson, J. G., and Krenitsky, T. A. 2-Amino-6-methoxypurine arabinoside (506U): an agent for T-cell malignancies. Cancer Res., 55: 3352-3355, 1995.
6. Cohen, A., Lee, J. W. W., and Gelfand, E. W. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood, 61: 660-666, 1983.
7. Shewach, D. S., Daddona, P. E., Ashcraft, E., and Mitchell, B. S. Differential metabolism of 9-β-D-arabinofuranosylguanine in human leukemic cells. Cancer Res., 49: 6498-6502, 1989.
8. Ullman, B., and Martin, D. W. Specific cytotoxicity of arabinosylguanine toward cultured T-lymphoblasts. J. Clin. Invest., 74: 951-955, 1984.
9. Shewach, D. S., and Mitchell, B. S. Differential metabolism of 9-β-D-arabinofuranosylguanine in human leukemic cells. Cancer Res., 45: 1008-1014, 1985.
10. Barker, J., and Lewis, R. A. Deoxyguanosine kinase of neonatal mouse skin tissue. Biochem. Biophys. Acta, 658: 111-123, 1981.
11. Gandhi, V., Mineishi, S., Huang, P., Yang, Y., Chubb, S., Chapman, A. J., Nowak, B. J., Hertel, L. W., and Plunkett, W. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin. Oncol., 22: 61-67, 1995.
12. Wang, L., Karlsson, A., Arnér, E. S. J., and Ericksson, S. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. J. Biol. Chem., 268: 22847-22852, 1993.
13. Carson, D. A., Kaye, J., and Seegmiller, J. E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc. Natl. Acad. Sci. USA, 14: 5677-5681, 1977.
14. Carson, D. A., Kaye, J., and Wasson, D. B. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J. Immunol., 126: 348-352, 1981.
15. Carson, D. A., Wasson, D. B., Lakon, E., and Kamatani, N. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc. Natl. Acad. Sci. USA, 79: 3848-3852, 1981.
16. Kurtzberg, J., Keating, M., Moore, J., Gandhi, V., Blaney, S., Gold, S., Ernst, T., Henslee-Downey, J., Chang, A., Kisor, D., Plunkett, W., and Mitchell, B. 9-β-D-Arabinofuranosyl-6-methoxy-9H-guanine (GW506U: compound 506U) is highly active in patients with T-cell malignancies: results of a phase I trial in pediatric and adult patients with refractory hematological malignancies. Blood, 88: 669a, 1996.
17. Gandhi, V., Kisor, D., Rodriguez, Jr., C. O., Mitchell, B. S., Kurtzberg, J., Keating, M. J., and Plunkett, W. Pharmacokinetics of arabinosylguanine (ara-G) and its triphosphate (ara-GTP) during a phase I trial of compound GW506U in refractory hematological malignancies: correlation with response. Blood, 88: 670a, 1996.
18. Gandhi, V., Nowak, B., Keating, M. J., and Plunkett, W. Modulation of 1-β-D-arabinofuranosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood, 74: 2070-2075, 1989.
19. Liliemark, J. O., Plunkett, W., and Dixon, D. O. Relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic cells during therapy with high dose 1-β-D-arabinofuranosylcytosine. Cancer Res., 45: 5952-5957, 1985.
20. Plunkett, W., Hug, V., Keating, M. J., and Chubb, S. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res., 40: 588-591, 1980.
21. Lewis, R. A., and Link, L. Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver. Biochem. Pharmacol., 38: 2001-2006, 1989.
22. Watkins, L. F., and Lewis, R. A. The metabolism of deoxyguanosine in mitochondria: a characterization of the phosphorylation process which occurs in intact mitochondria. Biochim. Biophys. Acta, 923: 103-108, 1987.
23. Krenitsky, T. A., Tuttle, J. V., Koszalka, G. W., Chen, I. S., Beacham, L. M., Rideout, J. L., and Elion, G. B. Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity. J. Biol. Chem., 251: 4055-4061, 1976.
24. Ives, D. W., and Durham, J. P. Deoxycytidine kinase III. Kinetics and allosteric regulation of the calf thymus enzyme. J. Biol. Chem., 245: 2285-2292, 1970.
25. Coleman, C. N., Stoller, R. G., Drake, J. C., and Chabner, B. A. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood, 46: 791-803, 1975.
26. Datta, N. S., Shewach, D. S., Mitchell, B. S., and Fox, I. H. Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. J. Biol. Chem., 264: 9359-9364, 1989.
27. Gower, W. R., Jr., Carr, M. C., and Ives, D. H. Deoxyguanosine kinase: distinct molecular forms in mitochondria and cytosol. J. Biol. Chem., 254: 2180-2183, 1979.
28. Seymour, J. F., Huang, P., Plunkett, W., and Gandhi, V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin. Cancer Res., 2: 653-658, 1996.
29. Kufe, D, W., Major, P. R., Egan, E. M., and Beardsley, G. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 255: 8997-9000, 1980.
30. Major, P. P., Egan, E. M., Beardsley, G. P., Minden, M. D., and Kufe, D. W. Lethality of human myoblasts correlated with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl. Acad. Sci. USA, 78: 3235-3239, 1981.
31. Cohen, A., Lee, J. W. W., Dosch, H-M., and Gelfand, E. W. The expression of deoxyguanosine toxicity in T-lymphocytes at different stages of maturation. J. Immunol., 125: 1578-1581, 1980.
32. Momparler, R. L., and Fischer, G. A. Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties and kinetic studies with 1-β-D-arabinofuranosylcytosine. J. Biol. Chem., 243: 4298-4304, 1968.
33. Heinemann, V., Hertel, L. W., Grindley, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
34. Shewach, D. S., Reynolds, K. K., and Hertel, L. Nucleotide specificity of human deoxycytidine kinase. Mol. Pharmacol., 42: 518-524, 1992.
35. Gandhi, V., Kemena, A., Keating, M. J., and Plunkett, W. Fludarabine infusion potentiates 1-β-D-arabinofuranosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res., 52: 897-903, 1992.
36. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Fludarabine potentiates metabolism of 1-β-D-arabinofuranosylcytosine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol., 11: 116-124, 1993.
37. Gandhi, V., and Plunkett, W. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukemia cells. Cancer Res., 48: 329-334, 1988.
38. Estey, E. H., Plunkett, W., Gandhi, V., Rios, M. B., Kantarjian, H., and Keating, M. J. Fludarabine and 1-β-D-arabinofuranosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma, 4: 343-350, 1993.